The key point of this finding is that the expression of GRP78 in COVID‐19 patients has increased compared to controls, which may indicate that the SARS‐CoV‐2 virus, regardless of the immunosuppressive therapy, can be a risk factor for developing mucormycosis.20 The gene discussed is HSPA5; the disease is COVID-19.